ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
43 announcements
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
Morepen Laboratories announced promotions effective 27 October 2026 for two senior management personnel. Charanjeet Chitakara moves to Assistant Vice President (Quality Control) and Vivan Prashar to Vice President (Projects & Engineering).
Morepen filed its Q2FY27 Monitoring Agency Report confirming Nil deviation in QIP proceeds utilization. The company spent ₹1.12 crore on modernization and expansion during the quarter.
Q2 FY27 revenue Rs755 Cr (+81%), PAT Rs89 Cr (+117%), EBITDA margin 17.45% (+897bps). H1 revenue Rs1,330 Cr (+57%). CDMO scale-up drives mix.
Morepen hit record Q2 FY27 revenue up 81% and EBITDA up 273%, driven by CDMO scale-up. H1 EBITDA reached ₹220 Cr; API+CDMO capacity now 614 KL.
Morepen Laboratories Ltd reported revenue from operations of ₹746.5 Cr (+81.4% YoY) and net profit of ₹88.9 Cr (+117.4% YoY) for Q2 FY27.
Morepen Laboratories Limited announced a board meeting scheduled for October 27, 2026. The meeting will consider and approve the financial results for the quarter ended September 30, 2026.
The High Court of Himachal Pradesh quashed a GST show cause notice against Morepen Laboratories, resolving a demand of ₹117.94 Crore in the company's favour.
Morepen Laboratories Ltd has filed its shareholding pattern for the quarter ended September 30, 2026, in compliance with regulatory requirements.
Morepen Laboratories submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Tablets USP, marking a significant milestone in its integrated CDMO capabilities.
Morepen Laboratories held its 41st Annual General Meeting on September 26, 2026, to conduct routine business, including dividend declaration and approval of director appointments.
Morepen Laboratories has been assigned an 'Adequate' ESG rating of 'CRISIL ESG 60' by Crisil ESG Ratings & Analytics Limited based on publicly disclosed information.
Morepen Laboratories successfully completed the first phase of its manufacturing capacity expansion. Installed reactor capacity for API and CDMO operations increased from 535 KL to 614 KL.
Morepen Laboratories dispatched a notice to shareholders without registered emails providing the Annual Report 2025-26 weblink. The company proposed a final dividend of ₹0.20 per share.
Morepen Laboratories has scheduled its 41st Annual General Meeting for September 26, 2026. The board has proposed a final dividend of ₹0.20 per equity share.
Morepen Laboratories secured a multi-year CDMO mandate worth approximately ₹825 Crore from a global pharmaceutical firm. This represents one of the largest single mandates in the company's history.
Morepen Laboratories has invested Rs. 20 Crore via a rights issue in its wholly-owned subsidiary, Morepen RX Limited, to strengthen its capital base.
Morepen Laboratories' board recommended a final dividend of Rs. 0.20 per equity share for FY 2025-26. The record date for the dividend is September 19, 2026.
Morepen Laboratories Limited has re-appointed Sushil Suri as Executive Director for a 36-month term, effective October 20, 2026. The Board approved this management change.
Morepen Laboratories' Monitoring Agency Report for Q1 FY27 confirms usage of QIP proceeds. The company faces a GST show-cause notice of ₹117.94 crore.
Morepen Laboratories reported record Q1 FY27 revenue of Rs. 575.31 Crore, up 34% YoY. Net profit surged 394% to Rs. 56.35 Crore following CDMO commercialization.
Morepen delivers explosive Q1'FY27 growth with 207% EBITDA jump, driven by the first commercial CDMO dispatches and operational leverage. The 'Morepen 2.0' strategy shifts focus from commodity APIs to high-margin innovation-led manufacturing.
Morepen Laboratories Ltd reported revenue from operations of ₹570.1 Cr (+34.1% YoY) and net profit of ₹56.3 Cr (+393.9% YoY) for Q1 FY27.
Morepen Laboratories has scheduled a board meeting for August 4, 2026, to approve the financial results for the quarter ended June 30, 2026.
Morepen Laboratories' wholly owned subsidiary, Morepen Labs - FZCO, changed its name to Morepen Labs FZE following migration from IFZA to JAFZA, Dubai.
Morepen Laboratories started commercial supplies under an ₹825 Crore CDMO mandate. The first dispatch of ₹50 Crore was completed in Q1FY2026-27.
Mr. Sanjay Suri is elevated from Whole-time Director to Managing Director. The appointment is effective from 1st July 2026.
Morepen Laboratories clarified that the recent trading volume spurt is market-driven. No undisclosed price-sensitive events or pending announcements exist, ensuring market transparency.
Morepen Labs reported Q4 FY26 revenue of ₹472 Cr, up 22% YoY, while shifting focus toward long-term CDMO contracts and high-margin medical devices.
Morepen Labs reported a 69% YoY net profit rise to ₹20 Crore for Q4 FY26. Strong growth in medical devices and CDMO execution support long-term visibility.